40108-53-0

Upstream product

• 15601-44-2 (Z/E)-4-(4-chlorobenzylidene)-2-phenyl-1,3-oxazol-5(4H)-one 
• 104-88-1 4-chlorobenzaldehyde 
• 495-69-2 Hippuric Acid 

Downstream Products

• 126293-16-1 N-{(Z)-2-(4-Chloro-phenyl)-1-[1-(4-chloro-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-vinyl}-benzamide 
• 40108-65-4 5-(4-chlorobenzyl)-3-phenyl-1,2,4-triazin-6-(1H)-one 
• 126245-10-1 5-[1-(4-Chloro-phenyl)-meth-(Z)-ylidene]-3-{[1-(4-nitro-phenyl)-meth-(E)-ylidene]-amino}-2-phenyl-3,5-dihydro-imidazol-4-one 
• 126245-09-8 3-{[1-(2-Bromo-phenyl)-meth-(E)-ylidene]-amino}-5-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-2-phenyl-3,5-dihydro-imidazol-4-one 
• 126245-08-7 5-[1-(4-Chloro-phenyl)-meth-(Z)-ylidene]-3-{[1-(2-chloro-phenyl)-meth-(E)-ylidene]-amino}-2-phenyl-3,5-dihydro-imidazol-4-one 
• 126245-06-5 5-[1-(4-Chloro-phenyl)-meth-(Z)-ylidene]-2-phenyl-3-{[1-phenyl-meth-(E)-ylidene]-amino}-3,5-dihydro-imidazol-4-one 
• 126244-94-8 N-{(Z)-2-(4-Chloro-phenyl)-1-[1-(2-nitro-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-vinyl}-benzamide 
• 126293-15-0 N-[(Z)-1-[1-(2-Bromo-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-2-(4-chloro-phenyl)-vinyl]-benzamide 
• 126244-93-7 N-{(Z)-2-(4-Chloro-phenyl)-1-[1-phenyl-meth-(E)-ylidene-hydrazinocarbonyl]-vinyl}-benzamide 
• 126244-95-9 N-{(Z)-2-(4-Chloro-phenyl)-1-[1-(4-nitro-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-vinyl}-benzamide 
• 126293-14-9 N-{(Z)-2-(4-Chloro-phenyl)-1-[1-(2-chloro-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-vinyl}-benzamide 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of hydrazone incorporated 1,2,4-triazines as anticonvulsant agents

New hydrazone incorporated triazines were designed and synthesized using an appropriate synthetic route with regard to essential pharmacophores, and evaluated for their anticonvulsant activity through maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole-induced seizure (scPTZ) screenings. Among the tested compounds, 4-[{2-(5-(3-chlorobenzyl)-3-phenyl-1,2,4-triazine-6-yl)hydrazono} methyl]-N,N-dimethylaniline 6k (MES ED50 54.31, scPTZ ED50 92.01) and 4-[{2-(5-(4-chlorobenzyl)-3-phenyl-1,2,4-triazine-6-yl)hydrazono}methyl]-N,N-dimethylaniline 6r (MES ED50 46.05, scPTZ ED50 83.90) emerged as the most active anticonvulsant agents having GABAergic effects. Compounds 6k and 6r also showed lesser CNS depressant effect than the standard drug carbamazepine. To obtain further insights into the binding interactions of these molecules, molecular docking studies were carried out.